Copyright © 2012 Liyan Jiao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. F. Clavel and A. J. Hance, “HIV drug resistance,” The New England Journal of Medicine, vol. 350, no. 10, pp. 1023–1035, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
2. V. A. Johnson, F. Brun-Vezinet, B. Clotet et al., “Update of the drug resistance mutations in HIV-1: fall 2006,” Topics in HIV Medicine, vol. 14, no. 3, pp. 125–130, 2006. View at Scopus
3. S. G. Sarafianos, B. Marchand, K. Das et al., “Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition,” Journal of Molecular Biology, vol. 385, no. 3, pp. 693–713, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
4. M. Geitmann, T. Unge, and U. H. Danielson, “Interaction kinetic characterization of HIV-1 reverse transcriptase non-nucleoside inhibitor resistance,” Journal of Medicinal Chemistry, vol. 49, no. 8, pp. 2375–2387, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
5. W. P. Bannister, L. Ruiz, A. Cozzi-Lepri et al., “Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA,” AIDS, vol. 22, no. 3, pp. 367–376, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
6. F. Ceccherini-Silberstein, V. Svicher, T. Sing et al., “Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors,” Journal of Virology, vol. 81, no. 20, pp. 11507–11519, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
7. K. Deforche, R. J. Camacho, Z. Grossman et al., “Bayesian network analyses of resistance pathways against efavirenz and nevirapine,” AIDS, vol. 22, no. 16, pp. 2107–2115, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
8. L. Y. Jiao, Z. Y. Bao, H. P. Li, et al., “Evolvement of HIV-1 drug resistant mutations in vitro without drug pressure,” Chinese Journal of Microbiology and Immunology, vol. 30, no. 5, pp. 431–437, 2010.
9. M. J. Gonzales, T. D. Wu, J. Taylor et al., “Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors,” AIDS, vol. 17, no. 6, pp. 791–799, 2003. View at Publisher · View at Google Scholar · View at Scopus
10. S. Jiang, H. Xing, X. Si, Y. Wang, and Y. Shao, “Polymorphism of the protease and reverse transcriptase and drug resistance mutation patterns of HIV-1 subtype B prevailing in China,” Journal of Acquired Immune Deficiency Syndromes, vol. 42, no. 4, pp. 512–514, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
11. S. Sungkanuparph, W. Manosuthi, S. Kiertiburanakul, B. Piyavong, and W. Chantratita, “Evaluating the role of Etravirine in the second-line antiretrovinal therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting,” Current HIV Research, vol. 6, no. 5, pp. 474–476, 2008. View at Publisher · View at Google Scholar · View at Scopus
12. B. Taiwo, B. Chaplin, S. Penugonda et al., “Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1,” Current HIV Research, vol. 8, no. 3, pp. 194–198, 2010. View at Publisher · View at Google Scholar · View at Scopus
13. E. C. Reuman, S. Y. Rhee, S. P. Holmes, and R. W. Shafer, “Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations,” Journal of Antimicrobial Chemotherapy, vol. 65, no. 7, Article ID dkq140, pp. 1477–1485, 2010. View at Scopus
14. L. Bacheler, S. Jeffrey, G. Hanna et al., “Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy,” Journal of Virology, vol. 75, no. 11, pp. 4999–5008, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
15. S. H. Qari, R. Respess, H. Weinstock et al., “Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1,” Journal of Clinical Microbiology, vol. 40, no. 1, pp. 31–35, 2002. View at Publisher · View at Google Scholar · View at Scopus
16. B. Selmi, J. Deval, K. Alvarez et al., “The Y181C substitution in 3′-azido-3′-deoxythymidine-resistant human immunodeficiency virus, type 1, reverse transcriptase suppresses the ATP-mediated repair of the 3′-azido-3′-deoxythymidine 5′-monophosphate-terminated primer,” Journal of Biological Chemistry, vol. 278, no. 42, pp. 40464–40472, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
17. L. T. Bacheler, E. D. Anton, P. Kudish et al., “Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy,” Antimicrobial Agents and Chemotherapy, vol. 44, no. 9, pp. 2475–2484, 2000. View at Publisher · View at Google Scholar · View at Scopus
18. C. B. Moore, M. John, I. R. James, F. T. Christiansen, C. S. Witt, and S. A. Mallal, “Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level,” Science, vol. 296, no. 5572, pp. 1439–1443, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
19. H. Azijn, I. Tirry, J. Vingerhoets et al., “TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 2, pp. 718–727, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
20. J. Vingerhoets, L. Tambuyzer, H. Azijn et al., “Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies,” AIDS, vol. 24, no. 4, pp. 503–514, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
21. J. Vingerhoets, H. Azijn, E. Fransen et al., “TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments,” Journal of Virology, vol. 79, no. 20, pp. 12773–12782, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
22. K. Das, A. D. Clark Jr., P. J. Lewi et al., “Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (Etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants,” Journal of Medicinal Chemistry, vol. 47, no. 10, pp. 2550–2560, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus